From http://projects.propublica.org/docdollars. © Copyright 2011 Pro Publica Inc.
Drug companies have long kept secret details of the payments they make to doctors and other health professionals for promoting their drugs. But 12 companies have begun publicizing the information, some because of legal settlements. ProPublica pulled their disclosures into a database so patients can search for their doctor. Accepting payments isn’t necessarily wrong, but it can raise ethical issues. Read more about the data »
Updated Sept. 7, 2011.
About this Database
Our Stories
Piercing the Veil, More Drug Companies Reveal Payments to Doctors
An update of ProPublica’s Dollars for Docs database includes more than $760 million in payments from 12 pharmaceutical companies to physicians and other health-care providers for consulting, speaking, research and expenses.
Also:
Local Stories Based on This Data
Interested in getting our Dollars for Docs data for use in your research or reporting? Find out how.
- WZTV FOX 17: SPECIAL REPORT: Doctors and Drugs
- The Tribune: Doctors face dilemma over compensation from drug companies
- Daily Hampshire Gazette: Rules shine light on drug firms' ties to doctors, raising questions about ethics
- Democrat and Chronicle: URMC gets better grade in conflict-of-interest report card
- Providence Journal: Doctors’ ties to drug makers get scrutiny
- KOAA.com: If your doctor was getting money from drug companies would you want to know about it?
- KOAA.com: Local doctors paid $1.5 million by drug companies
- KTRE ABC 9: East Texas docs paid by drug companies
- San Rafael Patch: How Much Does Your Doctor Take from Drug Companies?
- Berkeley Patch: How Much Does Your Doctor Take from Drug Companies?
Payments in Your State
Click on a state name to see the disclosed payments made to healthcare practitioners there. Notes: Allergan is not included in the state or national totals because it reports payments in ranges. Also, Valeant did not report payments in the fourth quarter of 2010.
| Name | Total |
| Alabama | $11,088,674 |
| Alaska | $263,333 |
| Arizona | $12,171,278 |
| Arkansas | $4,953,714 |
| California | $89,422,406 |
| Colorado | $13,383,820 |
| Connecticut | $10,835,250 |
| Delaware | $1,921,487 |
| District of Columbia | $3,619,223 |
| Florida | $56,001,451 |
| Georgia | $20,014,467 |
| Hawaii | $1,415,005 |
| Idaho | $2,555,576 |
| Illinois | $24,988,591 |
| Indiana | $13,878,303 |
| Iowa | $5,215,997 |
| Kansas | $9,223,710 |
| Kentucky | $10,909,633 |
| Louisiana | $8,502,889 |
| Maine | $1,244,415 |
| Maryland | $18,635,466 |
| Massachusetts | $22,135,703 |
| Michigan | $21,542,619 |
| Minnesota | $10,706,336 |
| Mississippi | $4,447,250 |
| Missouri | $18,902,337 |
| Montana | $692,983 |
| Nebraska | $5,059,794 |
| Nevada | $5,273,745 |
| New Hampshire | $2,742,608 |
| New Jersey | $21,773,190 |
| New Mexico | $2,166,325 |
| New York | $60,145,727 |
| North Carolina | $29,592,466 |
| North Dakota | $1,322,998 |
| Ohio | $33,819,224 |
| Oklahoma | $6,303,237 |
| Oregon | $5,937,530 |
| Pennsylvania | $40,064,872 |
| Rhode Island | $5,664,244 |
| South Carolina | $10,073,500 |
| South Dakota | $803,491 |
| Tennessee | $20,863,412 |
| Texas | $59,499,510 |
| Utah | $7,586,132 |
| Vermont | $768,856 |
| Virginia | $13,170,777 |
| Washington | $11,909,748 |
| West Virginia | $3,343,424 |
| Wisconsin | $9,229,426 |
| Wyoming | $319,996 |
| Puerto Rico | $4,789,479 |
| [Unknown State] | $389,294 |
Company Disclosures
The totals listed here range widely in scope and time period, and so aren't directly comparable. Some companies have added new data since we last downloaded their information.
| Name | Total |
|---|---|
|
Allergan Disclosure period: Q3 through Q4, 2010 |
n/a |
|
AstraZeneca Disclosure period: Q1, 2010 through Q1, 2011 |
$37.2 M |
|
Cephalon Disclosure period: Q1, 2009 through Q2, 2011 |
$49.3 M |
|
EMD Serono Disclosure period: Q1, 2011 |
$257 K |
|
Eli Lilly Disclosure period: Q1, 2009 through Q1, 2011 |
$206.1 M |
|
GlaxoSmithKline Disclosure period: Q2, 2009 through Q1, 2011 |
$147.2 M |
|
Johnson & Johnson Disclosure period: Q1 through Q4, 2010 |
$17.9 M |
|
Merck Disclosure period: Q3, 2009 through Q4, 2010 |
$29.8 M |
|
Novartis Disclosure period: Q4, 2010 |
$7.6 M |
|
Pfizer Disclosure period: Q3, 2009 through Q1, 2011 |
$259.6 M |
|
Valeant Disclosure period: Q1, 2010 through Q1, 2011 |
$477.2 K |
|
ViiV Disclosure period: Q1 through Q4, 2010 |
$4.3 M |